<div id="readability-page-1"><p>Voya Investment Management LLC decreased its holdings in shares of  Cencora, Inc. (NYSE:COR - Free Report) by 17.7% during the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 373,494 shares of the company's stock after selling 80,326 shares during the quarter. Voya Investment Management LLC owned about 0.19% of Cencora worth $116,728,000 as of its most recent SEC filing.</p><ul><li>Top 3 S&amp;P 500 Winners in a Losing Market</li></ul><p>Other institutional investors have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. grew its holdings in  Cencora by 1.6% in the third quarter. Contravisory Investment Management Inc. now owns 5,469 shares of the company's stock valued at $1,709,000 after purchasing an additional 87 shares during the period.  Wedmont Private Capital grew its stake in shares of  Cencora by 11.4% during the 3rd quarter. Wedmont Private Capital now owns 2,830 shares of the company's stock valued at $874,000 after buying an additional 289 shares during the period.  Czech National Bank increased its holdings in shares of  Cencora by 16.8% during the 3rd quarter. Czech National Bank now owns 49,240 shares of the company's stock worth $15,389,000 after buying an additional 7,075 shares during the last quarter.  Assenagon Asset Management S.A. raised its position in shares of  Cencora by 915.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 353,021 shares of the company's stock worth $110,330,000 after buying an additional 318,250 shares during the period.  Finally, Carolina Wealth Advisors LLC boosted its holdings in  Cencora by 27.9% in the third quarter. Carolina Wealth Advisors LLC now owns 6,624 shares of the company's stock valued at $2,070,000 after acquiring an additional 1,444 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Wall Street Analyst Weigh In</h2><p>COR has been the topic of a number of research reports. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, November 10th. Barclays initiated coverage on shares of Cencora in a research report on Monday, December 8th. They set an &#34;overweight&#34; rating and a $400.00 target price for the company. Robert W. Baird  set a $392.00 price objective on shares of Cencora in a research report on Tuesday. Wall Street Zen downgraded shares of Cencora from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, November 28th. Finally, Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 6th. One analyst  has rated the stock with a Strong Buy rating, eight have assigned  a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $373.25.</p><ul><li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li></ul><p><b>View Our Latest Research Report on Cencora</b></p><h2>Cencora Stock Performance</h2><p>Cencora stock opened at $341.07 on Friday. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm's fifty day moving average price is $346.49 and its 200 day moving average price is $313.01. The company has a market capitalization of $66.16 billion, a price-to-earnings ratio of 42.90, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54. </p><ul><li>Teva Pharma is the way to play the re-rise of generic drugs </li></ul><p>Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the firm earned $3.34 earnings per share. The company's revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS.  On average, research analysts forecast that  Cencora, Inc. will post 15.37 EPS for the current fiscal year. </p><h2>Cencora Increases Dividend</h2><p>The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora's previous quarterly dividend of $0.55. Cencora's dividend payout ratio (DPR) is presently 30.19%. </p><h2>Insider Activity</h2><p>In other news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.80% of the stock is currently owned by insiders. </p><h2>About Cencora</h2> (Free Report)<p>Cencora <span>NYSE: COR<span></span></span> is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.  </p><p>Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.</p><h2>See Also</h2><ul><li>Five stocks we like better than Cencora</li><li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li><li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li><li>What is MarketRank™? How to Use it</li><li>MarketBeat Week in Review – 12/15 - 12/19</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li></ul><p><strong>Want to see what other hedge funds are holding COR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cencora Right Now?</h2><p>Before you consider Cencora, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Voya Investment Management LLC reduced its stake in Cencora, Inc. by 17.7% in the 3rd quarter, now holding 373,494 shares worth $116.73 million. Other institutional investors also adjusted their positions. Analysts have mixed ratings on Cencora, with a consensus of 'Moderate Buy' and an average target price of $373.25. Cencora reported strong earnings and revenue growth, and increased its dividend. The stock has a market cap of $66.16 billion and a P/E ratio of 42.90.</p>

Voya Investment Management LLC Trims Position in Cencora, Inc. $COR